retatrutide developer eli lilly Lilly's hits Phase III goals with FDA filing planned for 2027 Lilly shares safety, tolerability data

TRIUMPH-4: the first Phase 3 result (December 2025) TRIUMPH-4 was a 68-week trial in 445 adults with obesity or overweight who also had knee osteoarthritis, and no diabetes

For a detailed statement, please see the University of Illinois Copyright Information and Policies here.

Studies show: Lowering inflammation with GLP-1s can slow the rate of joint damage in RA If you have RA and obesity or diabetes, takingGLP-1 meds can mean fewer flares and less need for extra medicine

Patients should monitor their symptom patterns and discuss timing adjustments with their healthcare provider if side effects are limiting treatment adherence

Inducible nitric oxide synthase (iNOS) and nitric oxide (NO) are important mediators of reflux-induced cell signalling in esophageal cells